New fully human monoclonal antibody or monoclonal antibody fragment, bispecific antibody or an immunoconjugate comprising heavy chain and light chain, used in manufacture of pharmaceutical composition against Cytomegalovirus for treatment, prevention or diagnosis of Cytomegalovirus
	SYED S; AHMED S S; AHMED K
	2023-10-30
专利权人	TECHINVENTION LIFECARE PRIVATE LTD (TECH-Non-standard)
申请日期	2023-10-30
专利号	IN202321073688-A
成果简介	NOVELTY - Fully human monoclonal antibody or monoclonal antibody fragment, bispecific antibody or an immunoconjugate is new, where human monoclonal antibody or monoclonal antibody fragment, bispecific antibody or an immunoconjugate comprises heavy chain and light chain. The sequence of heavy chain having 90% identity is selected from sequences comprising 112 amino acid sequence (SEQ ID NO: 1), 107 amino acid sequence (SEQ ID NOs: 2, and 14), 106 amino acid sequence (SEQ ID NO: 3, 9, 15), 109 amino acid sequence (SEQ ID NOs: 4, and 16), 110 amino acid sequence (SEQ ID NOs: 5, 12, and 13), 112 amino acid sequence (SEQ ID NOs: 6, 7, and 11), 108 amino acid sequence (SEQ ID NO: 8), and 111 amino acid sequence (SEQ ID NO: 10), given in the specification. USE - Fully human monoclonal antibody or monoclonal antibody fragment, bispecific antibody or an immunoconjugate used in manufacture of pharmaceutical composition against Cytomegalovirus for treatment, prevention or diagnosis of Cytomegalovirus, where cytomegalovirus is selected from Herpesviridae family (all claimed). ADVANTAGE - The fully human monoclonal antibody or monoclonal antibody fragment, bispecific antibody or an immunoconjugate has the ability of neutralization of cytomegalovirus (CMV) and it is sensitive and specific while interacting with target sites on CMV glycoprotein. DETAILED DESCRIPTION - Fully human monoclonal antibody or monoclonal antibody fragment, bispecific antibody or an immunoconjugate is new, where human monoclonal antibody or monoclonal antibody fragment, bispecific antibody or an immunoconjugate comprises heavy chain and light chain. The sequence of heavy chain having 90% identity is selected from sequences comprising 112 amino acid sequence (SEQ ID NO: 1), 107 amino acid sequence (SEQ ID NOs: 2, and 14), 106 amino acid sequence (SEQ ID NO: 3, 9, 15), 109 amino acid sequence (SEQ ID NOs: 4, and 16), 110 amino acid sequence (SEQ ID NOs: 5, 12, and 13), 112 amino acid sequence (SEQ ID NOs: 6, 7, and 11), 108 amino acid sequence (SEQ ID NO: 8), and 111 amino acid sequence (SEQ ID NO: 10), given in the specification; and sequence of light chain having 90% identity is selected from sequences comprising 110 amino acid sequence (SEQ ID NO: 17, 24, 29, and 36), 112 amino acid sequence (SEQ ID NO: 18, 19, 23, 25, 30, 31, and 35), 108 amino acid sequence (SEQ ID NO: 20), 106 amino acid sequence (SEQ ID NO: 21, 27, 32, and 33), 111 amino acid sequence (SEQ ID NO: 22, and 34), 107 amino acid sequence (SEQ ID NO: 26), and 109 amino acid sequence (SEQ ID NO: 28), given in the specification. INDEPENDENT CLAIMS are included for: Pharmaceutical composition, which comprises the antibody and a pharmaceutically acceptable carrier; and Method for preparation of fully human monoclonal antibody or monoclonal antibody fragment, bispecific antibody or an immunoconjugate.
IPC 分类号	A61K-039/42 ; C07K-016/08 ; C07K-016/10 ; C12N-015/10 ; C12Q-001/68 ; G01N-033/577
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/19403
专题	中国科学院新疆生态与地理研究所
作者单位	TECHINVENTION LIFECARE PRIVATE LTD (TECH-Non-standard)
推荐引用方式 GB/T 7714	SYED S,AHMED S S,AHMED K. New fully human monoclonal antibody or monoclonal antibody fragment, bispecific antibody or an immunoconjugate comprising heavy chain and light chain, used in manufacture of pharmaceutical composition against Cytomegalovirus for treatment, prevention or diagnosis of Cytomegalovirus. IN202321073688-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。